Regions of hypoxia are present in the majority of solid tumors mainly because of poor and defective vascularization.
Regions of hypoxia are present in the majority of solid tumors mainly because of poor and defective vascularization. 1, 2) Evidence indicating that hypoxic cells exist in the tumors has been obtained from microscopic analysis of histological sections 3, 4) and radiobiological studies. 5) Oxygen is required for the cytotoxic effects of many cancer chemotherapeutic drugs and radiation, and hypoxic tumor cells are resistant to the conventional chemotherapy and radiotherapy. 6) Moreover, hypoxia also selects for more aggressive and metastatic cancer phenotypes that are associated with poor prognosis. 7) To conquer the therapeutic resistance induced by hypoxia, several compounds have been developed as prodrugs that are preferentially bioactivated in the hypoxic cells. The most advanced bioreductive drug, tirapazamine, is in phase III clinical trials in combination with cisplatin. 8) To identify a novel hypoxia-selective cytotoxin, we screened 20000 cultured broths of microorganisms and found that rakicidin A showed significant hypoxia-selective cytotoxicity. Rakicidin A was approximately 17.5-fold more cytotoxic under hypoxic than under normoxic conditions. In this paper, we describe the hypoxia-selective cytotoxicity of rakicidin A.
MATERIALS AND METHODS
Cell Culture CHO chinese hamster ovary cells were maintained in minimum essential medium alpha medium (a-MEM) supplemented with 10% fetal bovine serum (ICN Biomedicals, Costa Mesa, CA, U.S.A.) and kanamycin (50 mg/ml). Human colorectal adenocarcinoma cell lines HCT-8 and DLD-1, human glioblastoma cell lines U251 and SF268, human prostate cancer cell lines PC-3 and LNCaP, human pancreatic adenocarcinomas cell line PANC-1 were maintained in RPMI1640 with 10% fetal bovine serum and kanamycin (50 mg/ml). A stable transformant of CHO cells was established by the transfection of the HIF-1-dependent luciferase (5ϫHRE/pGL3/VEGF/E1b) and neomycin resistant genes as previously described. 9) Stably transfected cells were maintained in a-MEM supplemented with 10% fetal bovine serum and kanamycin (50 mg/ml). Cells were cultured at 37°C in a humidified incubator containing 5% CO 2 (normoxia).
Materials Materials used were as follows: [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT), CoCl 2 , actinomycin D, bleomycin, camptothecin, chlorambucil, doxorubicin, etoposide, melphalan, mitomycin C, streptonigrin, taxol and tubercidin from Sigma Aldrich, St. Louis, U.S.A.; cisplatin from BioVision, California, U.S.A.; neocarzinostatin from Astellas Pharma, Inc., Japan; glutathione from Cayman Chemical Company, Michigan, U.S.A.; a-tocopherol and N-acetyl-L-cysteine from LKT Laboratories, Inc., Minnesota, U.S.A. All reagents were initially dissolved in dimethyl sulfoxide (DMSO) (Sigma) and diluted with the medium for assay.
Screening CHO cells were seeded at a density of 1ϫ10 4 /100 ml medium per well into a pair of 96-well microplates and cultured for 24 h to assure complete adherence of the cells to the plates. The cultured cells were treated with fermentation broths of microorganisms and one plate was placed in a humidified incubator containing 5% CO 2 (normoxic condition) and another was placed in hypoxic conditions. Hypoxic treatment was performed by incubating cells at 37°C in an air-tight chamber (Forma Scientific, Inc., Marietta, OH, U.S.A.) filled with a mixture of 90% N 2 , 5% CO 2 and 5% H 2 . After 2 d of hypoxic treatment, the cytotoxic effects were measured by MTT method under normoxic conditions.
Reporter Gene Assay Stably transfected cells were seeded at 1ϫ10 4 cells/well in 96-well microplates 1 d before the following treatment. They were treated with drugs for 15 h under hypoxic conditions and then harvested for determination of the luciferase activity. The assay was carried out using the Luciferase Assay System from Promega.
RESULTS

Anticancer Drug Resistance Induced by Hypoxia
Tumor hypoxia causes resistance to chemotherapy. To confirm this effect of hypoxia on the cytotoxicities of various anticancer drugs, we compared the IC 50 values under hypoxic to normoxic conditions (Table 1) . Thus, most anticancer drugs experimented with here showed the drug resistance against CHO cells under hypoxic conditions. Many anti-cancer drugs require oxygen for their cytotoxic effects. However, only mitomycin C showed a lower IC 50 value under hypoxic than under normoxic conditions. Mitomycin C is an alkylating agent used in cancer chemotherapy and is known as a hypoxia-selective cytotoxin. Mitomycin C requires reductive activation to cross-link the DNA of tumor cells and express its anticancer activity. 10) Hypoxia augments the reductive activity and cytotoxic effect of mitomycin C. On the other hand, hypoxia induced approximately 10-fold drug resistance to etoposide, neocarzinostatin and streptonigrin.
The Hypoxia-Selective Cytotoxicity of Rakicidin A To identify a novel hypoxia-selective cytotoxin, we screened 20000 cultured broths of microorganisms and found that a fermentation broth produced by Micromonospora strain ML99-43F1 showed significant hypoxia-selective cytotoxicity against CHO cells. The active substance was purified from the cultured broth (64 l) of strain ML99-43F1 through silica gel column chromatography, LH-20 column chromatography and HPLC. Finally, the active substance (24.9 mg) was isolated as white powders and determined to be rakicidin A by MS and NMR analysis.
11) The structure of rakicidin A is shown in Fig. 1 . Rakicidin A was found to have antitumor activity in vitro.
11)
Rakicidin A showed dramatically enhanced cytotoxicity under the hypoxic conditions compared to normoxic conditions. We confirmed the hypoxia selectivity of rakicidin A against several human tumor cell lines (Table 2) . Rakicidin A showed the hypoxia-selective cytotoxicity against all human tumor cell lines examined. The most potent effect of Rakicidin A was observed against human colorectal adenocarcinoma cell line HCT-8. Rakicidin A was approximately 17.5-fold more cytotoxic under hypoxic than under normoxic conditions. Consequently, we examined whether hypoxia induces resistance to other anticancer drug in HCT-8. As shown in Table 3 , hypoxia induced more severe drug resistance on HCT-8. Even mitomycin C did not show hypoxia-selective cytotoxicity on HCT-8, and HCT-8 was 100-fold resistance to streptonigrin under hypoxic conditions. On the other hand, poor selectivity of rakicidin A under hypoxic conditions was observed against human colorectal adenocarcinoma cell line DLD-1 and human prostate cancer cell line PC-3. But then, rakicidin A showed 2.8-fold stronger cytotoxicity under hypoxic conditions on DLD-1 and PC-3, and this hypoxia selectivity is reasonably good. Because most anticancer drugs showed the drug resistance against CHO cells under hypoxic conditions except for mitomycin C (Table 1) . These different hypoxia selectivities of rakicidin A might be caused by the difference in proliferation rate under hypoxic conditions. To test this possibility, we compared final cell numbers after normoxic or hypoxic treatment (Table 4) . But we could not find general relativity between the hypoxia selectivities of rakicidin A and proliferation rates.
Next, we investigated the time course of cytotoxicity of rakicidin A under normoxic and hypoxic conditions ( Fig. 2A) . Although the hypoxia-selective cytotoxicity of rakicidin A was observed by 8 h hypoxic treatment, the effect of hypoxia on cell proliferation was not observed till 24 h hypoxic treat- (Fig. 2B) .
The Effect of CoCl 2 on the Rakicidin A Cytotoxicity CoCl 2 is known to mimic hypoxia, induces hypoxia-inducible factor-1 (HIF-1) expression, and stimulates erythropoietin production under normoxia. 12) To assess the effect of CoCl 2 on the rakicidin A cytotoxicity, HCT-8 cells were treated with 100 or 250 mM CoCl 2 . However, CoCl 2 treatment did not show enhanced cytotoxicity unlike under hypoxic conditions (Fig. 3) . These results suggest that rakicidin A requires actual hypoxia for the enhancement of its cytotoxicity.
The Effect of Antioxidant on the Rakicidin A Cytotoxicity Some anticancer drugs require oxygen for their cytotoxicities to produce oxygen radicals in the tumor cells. On the other hand, the oxygen radicals might decrease the rakicidin A cytotoxicity under normoxic conditions because rakicidin A is a labile compound. To examine this hypothesis, HCT-8 cells were treated with the antioxidants, glutathione, a-tocopherol and N-acetyl-L-cysteine. However, all three antioxidants had no effect on the rakicidin A cytotoxicity under normoxic conditions (Fig. 4) . The Effect of Rakicidin A on the HIF-1 Dependent Luciferase Activity Hypoxia-inducible factor-1 (HIF-1) is a central mediator of cellular responses to low oxygen and activates transcription of a large number of target genes for adaptation and survival under hypoxia. 13) Hypoxia elicits the induction of the multidrug resistance (MDR1) gene and increases P-glycoprotein expression through the HIF-1 activation. 14) To assess the affect of rakicidin A on the HIF-1 activation, we transfected CHO cells with a luciferase reporter gene construct containing 5 copies of an HIF-1 binding site derived from the human VEGF promoter and established a stable clone. Although the luciferase activity was significantly induced (60-fold) in response to hypoxia, rakicidin A did not affect the HIF-1 activation (Fig. 5A) . In contrast, HIF-1 transcriptional activity was significantly inhibited by HIF-1 inhibitor tartrolone C 15) in a dose-dependent manner under hypoxic conditions (Fig. 5B) .
DISCUSSION
Hypoxia is a common feature of many solid tumors and contributes to their progression. Hypoxic cells in the tumor are not only involved in therapeutic resistance in chemotherapy and radiotherapy but are also relevant to tumor angiogenesis. Then again, the unique presence of hypoxic cells provides an attractive target for selective cancer therapy.
To identify a novel hypoxia-selective cytotoxin, we screened 20000 cultured broths of microorganisms. In 20000 cultured broths of microorganisms, most broths screened were ineffective under hypoxic conditions. Although several cultured broths showed equivalent cytotoxicity under both normoxic and hypoxic conditions, only a sole fermentation broth produced by Micromonospora strain ML99-43F1 showed significant hypoxia-selective cytotoxicity. Table 1 reflects the results of the screening. Most anticancer drugs experimented with here showed the drug resistance against CHO cells under hypoxic conditions except for mitomycin C. Mitomycin C is a bioreductive alkylating agent with selective toxicity toward hypoxic tumor cells. 16, 17) There are several causes of resistance induced by hypoxia. Some anticancer drugs require oxygen for their cytotoxic effects. For example, streptonigrin produces hydroxy radicals that induce the breakage of DNA strands, 18) and the oxygen radicals generated from doxorubicin and mitomycin C may play a critical role in their toxicity to human tumor cells. 19, 20) Furthermore, the tumor cells exhibit aberrant cell cycle progression under hypoxic conditions. Hypoxia induced G 1 arrest develops drug resistance because most anticancer drugs are primarily effective against rapidly dividing cells. Lastly, expression of a multidrug resistance transporter, P-glycoprotein, has been demonstrated to be regulated by hypoxia. 14) Rakicidin A showed dramatically enhanced cytotoxicity under the hypoxic conditions against several human tumor cell lines ( Table 2 ). The best selectivity was observed in HCT-8 and rakicidin A was approximately 17.5-fold more cytotoxic against HCT-8 under hypoxic than under normoxic conditions. In contrast, poor selectivity was observed in DLD-1 and PC-3 and rakicidin A showed 2.8-fold stronger cytotoxicity under hypoxic conditions. On the other hand, the respective cellular growth rates under hypoxic conditions were different (Table 4) . Although the growth rate of LNCaP was significantly depressed under hypoxic conditions, DLD-1 and SF268 were barely influenced by hypoxia. These results show no relation between the hypoxia selectivity of rakicidin A and proliferation rate. In addition, the time course study of cytotoxicity of rakicidin A under normoxic and hypoxic conditions showed that only 8 h hypoxic treatment induced selectivity effects ( Fig. 2A) .
CoCl 2 and antioxidants failed to imitate the hypoxia-selective cytotoxicity of rakicidin A under normoxic conditions, and rakicidin A did not show an inhibitory effect on the HIF-1 transcriptional activity under hypoxic conditions (Figs. 3-5) . Additionally, rakicidin A did not induce apoptosis under hypoxic conditions (data not shown). Thus, the action mechanism of the hypoxia-selective cytotoxicity of rakicidin A was unknown.
A number of hypoxia-selective cytotoxins were chemically synthesized and most them contain N-oxide or quinone structures. The N-oxide or quinone moieties are frequently reduced by cellular reductases to toxic products and show the hypoxia selectivities. 21) However rakicidin A does not contain them (Fig. 1) . Consequently, further research is needed to elucidate the action mechanism of the hypoxia-selective cytotoxicity of rakicidin A.
In summary, to identify a novel hypoxia-selective cytotoxin, we screened cultured broths of microorganisms and found that most broths screened were ineffective under hypoxic conditions. In this screening study, rakicidin A showed a unique hypoxia-selective cytotoxicity. The hypoxic cells in the tumor are recognized as an attractive target for the development of novel cancer therapeutics, and there is a possibility that rakicidin A acts as an antitumor agent for selective therapy against solid tumors.
